Archer-Daniels-Midland CompanyADM
▲ PositiveCapitalrelevance
ADM beats Q2 estimates and raises 2026 guidance, with strong segment profits.
Impact on stocks 2
Synthetic Biology (non-pharma)
Archer-Daniels-Midland Company
Corteva IncCTVA
Mentioned
Archer Daniels Midland reported second-quarter 2026 adjusted earnings of $1.84 per share, up 98% year over year and surpassing the Zacks Consensus Estimate of $1.42 by 29.6%, while revenues rose 7.1% to $22.68 billion, beating the consensus of $22.38 billion. The company raised its 2026 adjusted earnings guidance to approximately $5.15-$5.60 per share from the previous range of $4.15-$4.70, citing improved crushing and ethanol margins. Segment operating profit increased 75% year over year to $1.5 billion, with Ag Services and Oilseeds profit surging 129% to $867 million, Carbohydrate Solutions up 22% to $411 million, and Nutrition up 51% to $172 million. ADM also processed 9.5 million metric tons of oilseeds, up 4.7% from the prior-year quarter. Following the report, shares have gained about 10.1% over the past month, outperforming the S&P 500, and the consensus estimate has shifted upward by 14.23%.
Archer-Daniels-Midland CompanyADM beats Q2 estimates and raises 2026 guidance, with strong segment profits.
Corteva Inc